Thursday, March 28, 2024

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeBiotech-PharmaAbbVie Inc. (NYSE:ABBV)...

AbbVie Inc. (NYSE:ABBV) Plans with Bristol Myers Squibb Co (NYSE:BMY) To Lay off Jobs

The leading drugmakers Bristol Myers Squibb Co (NYSE:BMY) and AbbVie Inc. (NYSE:ABBV) informed California regulators that they want to remove up to 360 employees there in unrelated measures, according to papers filed with the state and made public earlier this week.

According to the documents, Bristol Myers planned to lay off up to 261 people in two distinct San Diego sites. According to a Bristol Myers representative, the job layoffs are the result of the company’s $4.1 billion acquisition of drug researcher Turning Point Therapeutics in August.

“All entering workers received retention packages related to ongoing service to BMS for a period of time and have been encouraged to apply to long-term employment at BMS once their retention period finishes,” stated a representative in an email.

Separately, AbbVie has informed the state that it intends to lay off up to 99 employees in Irvine, California. A request for comment was not returned by the corporation.

According to Bristol Myers Squibb, the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in RFS versus placebo at a pre-specified interim analysis (NYSE: BMY). There were no further safety signals detected throughout the research.

Gina Fusaro, PhD, development program lead, melanoma, Bristol Myers Squibb said,

“Stage IIB/C melanoma patients are at high risk of disease recurrence, with approximately one third of stage IIB and half of stage IIC patients experiencing recurrence within five years after surgery. The results of the CheckMate -76K study represent a significant advancement for patients with stage IIB/C melanoma and an extension of our legacy in the treatment of melanoma. Recurrence represents a life-altering event for people living with cancer. Treating with Opdivo in earlier stages of cancer, when the immune system may be more responsive, has the potential to help prevent recurrence – a critical goal of improving patient outcomes.”

The business will do a thorough analysis of the CheckMate -76K data and plans to share the findings at an upcoming medical conference as well as with health authorities. Bristol Myers Squibb expresses gratitude to the patients and scientists who took part in the CheckMate -76K clinical study.

Oracle Corp’s (NYSE: ORCL) Cloud Business Faces Headwinds: What Lies Ahead

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15% or $15.21 to trade at $111.50 in pre trading session on...

RTX Corp (NYSE: RTX) Updates 2023-2025 Outlook amid Engine Part Challenge

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03 per share, bringing its current trading price to $77.45. The company,...

GameStop Corp. (NYSE:GME) Quarter Report: Resilience amidst Market Turbulence

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after the market closes today. Shares were slightly down in the pre-trading...

Continue reading

RTX Corp (NYSE: RTX) Updates 2023-2025 Outlook amid Engine Part Challenge

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03 per share, bringing its current trading price to $77.45. The company, with a substantial market capitalization of $112.57 billion, has seen its shares trade within a...

GameStop Corp. (NYSE:GME) Quarter Report: Resilience amidst Market Turbulence

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after the market closes today. Shares were slightly down in the pre-trading session on Wednesday, September 6, 2023. Investors and market aficionados were eagerly awaiting the tech company's...

Nikola Corp. (NASDAQ: NKLA) Hit by Active Sellers on Profit in ‘Short Squeeze’

Shares of Nikola Corp. (NASDAQ: NKLA) drops in early trading session on Monday as the cutting into paper earnings for traders betting against the electric-vehicle company and setting them up for a short squeeze. According to S3 Partners LLC statistics,...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.